DEALS: Blackstone Group buys Cardinal Health unit for $3.3B


Blackstone Group buys Cardinal Health unit for $3.3B


DEALS

WHO

WITH

WHAT

SCOOP

Cardinal Health

Blackstone Group

$3.3B sale

Cardinal Health has struck a deal to sell its pharmaceutical technologies and services business to the Blackstone Group.

MDS

Molecular Devices

$615M buyout

MDS plans to combine Molecular Devices--which makes software and systems for researchers engaged in biochemical testing and cellular analysis--with MDS Sciex.

AstraZeneca

Argenta

$521M development deal

Argenta will work with AstraZeneca on a therapy for chronic obstructive pulmonary disease.

AstraZeneca

Palatin Technologies

$310 development deal

Palatin Technologies is developing obesity drugs.

Hikma

Ribosepharm

$45M buyout

Ribosepharm markets injectable generic oncology drugs.

Health Acquisition Corp.

PharmAthene

Merger

PharmAthene is going public through a merger with Health Acquisition Corp.

PsychoGenics

Amylin Pharmaceuticals

Merger

PsychoGenics and Amylin Pharmaceuticals have formed Psylin Neurosciences, a new company that will focus on the discovery and development of peptide hormones for treatment of psychiatric disorders.

Quotient BioResearch

HFL

Acquisition

Quotient BioResearch announced its launch with the acquisition of HFL, a UK-based firm that provides research and development support to pharmaceutical and biotech companies.

Pfizer

MediVas

Development deal

MediVas has teamed with Pfizer to develop new therapies for eye diseases. The pact will combine MediVas work in polymers with Pfizer's compounds.

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.